CONTEXT: Alcohol facilitates gamma-aminobutyric acid (GABA) function, and GABA type A (GABA(A)) receptor-facilitating agents suppress alcohol withdrawal symptoms. Advances in molecular neuroscience, genetics, and neuroimaging provide new insights into the role of brain GABA systems in short- and long-term alcohol effects. OBJECTIVE: To review the role of brain GABA systems in alcohol response, alcohol dependence, alcoholism vulnerability, and alcoholism pharmacotherapy. DESIGN: Literature review. RESULTS: Alcohol increases GABA release, raises neurosteroid levels, and may potently enhance the function of a GABA(A) receptor subclass that shows high affinity for GABA and neurosteroids, relative insensitivity to benzodiazepines, low chloride conductance, and an extrasynaptic location. Variation in GABA(A) receptor subunit genes may contribute to the vulnerability to alcoholism, particularly in the context of environmental risk factors. Alcohol dependence is associated with time-dependent changes in brain GABA(A) receptor density and subunit gene expression levels that contribute to a withdrawal-related deficit in GABA(A) receptor function. However, cortical GABA levels are not reduced during acute withdrawal. Benzodiazepine-assisted detoxification enhances a phasic component of GABA function. However, novel treatments target the tonic component of GABA neurotransmission mediated by benzodiazepine-insensitive GABA(A) receptors. Smoking attenuates withdrawal-related disturbances in brain GABA function, perhaps contributing to comorbid nicotine and alcohol dependence. The GABA systems show recovery with long-term sobriety. CONCLUSIONS: Recent research deepens our understanding of the role of GABA systems in alcohol action, alcohol dependence, and the vulnerability to alcoholism. Also, GABA(A) receptor subtype-selective treatments merit exploration for reducing withdrawal symptoms and drinking in alcohol-dependent individuals.
CONTEXT: Alcohol facilitates gamma-aminobutyric acid (GABA) function, and GABA type A (GABA(A)) receptor-facilitating agents suppress alcoholwithdrawal symptoms. Advances in molecular neuroscience, genetics, and neuroimaging provide new insights into the role of brain GABA systems in short- and long-term alcohol effects. OBJECTIVE: To review the role of brain GABA systems in alcohol response, alcohol dependence, alcoholism vulnerability, and alcoholism pharmacotherapy. DESIGN: Literature review. RESULTS:Alcohol increases GABA release, raises neurosteroid levels, and may potently enhance the function of a GABA(A) receptor subclass that shows high affinity for GABA and neurosteroids, relative insensitivity to benzodiazepines, low chloride conductance, and an extrasynaptic location. Variation in GABA(A) receptor subunit genes may contribute to the vulnerability to alcoholism, particularly in the context of environmental risk factors. Alcohol dependence is associated with time-dependent changes in brain GABA(A) receptor density and subunit gene expression levels that contribute to a withdrawal-related deficit in GABA(A) receptor function. However, cortical GABA levels are not reduced during acute withdrawal. Benzodiazepine-assisted detoxification enhances a phasic component of GABA function. However, novel treatments target the tonic component of GABA neurotransmission mediated by benzodiazepine-insensitive GABA(A) receptors. Smoking attenuates withdrawal-related disturbances in brain GABA function, perhaps contributing to comorbid nicotine and alcohol dependence. The GABA systems show recovery with long-term sobriety. CONCLUSIONS: Recent research deepens our understanding of the role of GABA systems in alcohol action, alcohol dependence, and the vulnerability to alcoholism. Also, GABA(A) receptor subtype-selective treatments merit exploration for reducing withdrawal symptoms and drinking in alcohol-dependent individuals.
Authors: Kelly P Cosgrove; Irina Esterlis; Graeme F Mason; Frederic Bois; Stephanie S O'Malley; John H Krystal Journal: Neuropharmacology Date: 2011-01-27 Impact factor: 5.250
Authors: Karen K Szumlinski; Mahdi E Diab; Raquel Friedman; Liezl M Henze; Kevin D Lominac; M Scott Bowers Journal: Psychopharmacology (Berl) Date: 2007-01-16 Impact factor: 4.530
Authors: Ismene L Petrakis; Elizabeth Ralevski; Ralitza Gueorguieva; Stephanie S O'Malley; Albert Arias; Kevin A Sevarino; Jane S Jane; Erin O'Brien; John H Krystal Journal: Addiction Date: 2017-10-12 Impact factor: 6.526
Authors: Jonathan Covault; Joel Gelernter; Kevin Jensen; Raymond Anton; Henry R Kranzler Journal: Neuropsychopharmacology Date: 2007-05-16 Impact factor: 7.853
Authors: Jason P Caplan; Lucy A Epstein; Davin K Quinn; Jonathan R Stevens; Theodore A Stern Journal: Neuropsychol Rev Date: 2007-08-16 Impact factor: 7.444
Authors: Rungnapa Hirunsatit; Elizabeth D George; Barbara K Lipska; Hani M Elwafi; Lisa Sander; Carolyn M Yrigollen; Joel Gelernter; Elena L Grigorenko; Jaakko Lappalainen; Shrikant Mane; Angus C Nairn; Joel E Kleinman; Arthur A Simen Journal: Pharmacogenet Genomics Date: 2009-01 Impact factor: 2.089
Authors: Mary-Anne Enoch; Colin A Hodgkinson; Qiaoping Yuan; Bernard Albaugh; Matti Virkkunen; David Goldman Journal: Neuropsychopharmacology Date: 2008-09-24 Impact factor: 7.853